{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:20:28Z","timestamp":1769599228090,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3683-2","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T14:05:15Z","timestamp":1549893915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden"],"prefix":"10.1186","volume":"19","author":[{"given":"Lefteris","family":"Floros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kuessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Posthumus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Bagshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sj\u00f6lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"issue":"3","key":"3683_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","volume":"52","author":"C Lass-Florl","year":"2009","unstructured":"Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197\u2013205.","journal-title":"Mycoses"},{"issue":"3","key":"3683_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"D Neofytos","year":"2009","unstructured":"Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265\u201373.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3683_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3201\/eid2007.140087","volume":"20","author":"D Bitar","year":"2014","unstructured":"Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20(7):1149\u201355.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"3683_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3683_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eimc.2011.01.010","volume":"29","author":"J Fortun","year":"2011","unstructured":"Fortun J, Carratala J, Gavalda J, Lizasoain M, Salavert M, de la Camara R, Borges M, Cervera C, Garnacho J, Lassaleta A, et al. Guidelines for the treatment of invasive fungal disease by aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 update. Enferm Infecc Microbiol Clin. 2011;29(6):435\u201354.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"121","key":"3683_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09059180.00001011","volume":"20","author":"M Kousha","year":"2011","unstructured":"Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20(121):156\u201374.","journal-title":"Eur Respir Rev"},{"issue":"Suppl 3","key":"3683_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12371","volume":"20","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5\u201326.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"3683_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3324\/haematol.2012.065110","volume":"98","author":"A Skiada","year":"2013","unstructured":"Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL, European conference on infections in L. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European conference on infections in leukemia (ECIL 3). Haematologica. 2013;98(4):492\u2013504.","journal-title":"Haematologica"},{"issue":"8","key":"3683_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/myc.12344","volume":"58","author":"L Klingspor","year":"2015","unstructured":"Klingspor L, Saaedi B, Ljungman P, Szakos A. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Mycoses. 2015;58(8):470\u20137.","journal-title":"Mycoses"},{"issue":"4","key":"3683_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","volume":"47","author":"G Chamilos","year":"2008","unstructured":"Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10020","key":"3683_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"7","key":"3683_CR12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337.","journal-title":"Lancet Infect Dis"},{"key":"3683_CR13","unstructured":"FDA Anti-infective Drugs Advisory Committee. Advisory Committee Briefing Document. Isavuconazonium: Invasive Aspergillosis and Invasive Mucormycosis [\n                    https:\/\/www.pharmamedtechbi.com\/~\/media\/Supporting%20Documents\/The%20Pink%20Sheet%20DAILY\/2015\/January\/12015%20AIDACB101FDA_Backgrounder.pdf\n                    \n                  ]. Accessed 17 Jan 2019."},{"issue":"4","key":"3683_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u2013e60.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3683_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoli C, Herbrecht R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344.","journal-title":"Haematologica"},{"issue":"1","key":"3683_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","volume":"34","author":"R Harrington","year":"2017","unstructured":"Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-effectiveness analysis of Isavuconazole vs. Voriconazole as first-line treatment for invasive aspergillosis. Adv Ther. 2017;34(1):207\u201320.","journal-title":"Adv Ther"},{"issue":"6","key":"3683_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1600-0609.2007.00850.x","volume":"78","author":"K Bruynesteyn","year":"2007","unstructured":"Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532\u20139.","journal-title":"Eur J Haematol"},{"key":"3683_CR18","unstructured":"European Medicines Agency. Summary of Product Characteristcs. VFEND 50 mg and 200 mg film-coated tablets, VFEND 200 mg powder for solution for infusion, VFEND 200 mg powder and solvent for solution for infusion, VFEND 40 mg\/ml powder for oral suspension. [\n                    https:\/\/www.medicines.org.uk\/emc\/product\/7977\n                    \n                  ]. Accessed 17 Jan 2019."},{"key":"3683_CR19","unstructured":"European Medicines Agency. Summary of Product Characteristics: Cresemba 100 mg hard capsules. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/5071\n                    \n                  . Accessed 17 Jan 2019."},{"key":"3683_CR20","unstructured":"European Medicines Agency. Summary of Product Characteristics: Cresemba 200 mg powder for concentrate for solution for infusion. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/5069\n                    \n                  . Accessed 17 Jan 2019."},{"key":"3683_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2217\/fmb-2016-0231","volume":"12","author":"E Bagshaw","year":"2017","unstructured":"Bagshaw E, Kuessner D, Posthumus J, Escrig C, Blackney M, Heimann SM, Cornely OA. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Future Microbiol. 2017;12:515\u201325.","journal-title":"Future Microbiol"},{"issue":"7","key":"3683_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","volume":"19","author":"D Horn","year":"2016","unstructured":"Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, Franks B, Shorr AF. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728\u201334.","journal-title":"J Med Econ"},{"issue":"10","key":"3683_CR23","doi-asserted-by":"publisher","first-page":"E396","DOI":"10.1111\/j.1469-0691.2012.03908.x","volume":"18","author":"A Xhaard","year":"2012","unstructured":"Xhaard A, Lanternier F, Porcher R, Dannaoui E, Bergeron A, Clement L, Lacroix C, Herbrecht R, Legrand F, Mohty M, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French multicentre cohort study (2003-2008). Clin Microbiol Infect. 2012;18(10):E396\u2013400.","journal-title":"Clin Microbiol Infect"},{"key":"3683_CR24","unstructured":"European Medicines Agency. Summary of Product Characteristics: AmBisome\u00ae 50 mg powder for solution for infusion (liposomal amphotericin B). \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/1236\n                    \n                  . Accessed 17 Jan 2019."},{"key":"3683_CR25","unstructured":"European Medicines Agency. Summary of Product Characteristics: Noxafil 100 mg Gastro-resistant Tablets. \n                    https:\/\/www.medicines.org.uk\/emc\/product\/5388\/smpc\n                    \n                  . Accessed 17 Jan 2019."},{"issue":"1","key":"3683_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","volume":"103","author":"AC Leenders","year":"1998","unstructured":"Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(1):205\u201312.","journal-title":"Br J Haematol"},{"key":"3683_CR27","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket: TLV price list \n                    https:\/\/www.tlv.se\/\n                    \n                  . Accessed 17 Jan 2019."},{"key":"3683_CR28","unstructured":"Apoteket [\n                    http:\/\/www.apoteket.se\n                    \n                  ]. Accessed 17 Jan 2019."},{"key":"3683_CR29","volume-title":"Price list. Inpatient daily cost at haematology clinic. Code: VD010","author":"Region Sk\u00e5ne","year":"2015","unstructured":"Region Sk\u00e5ne. Price list. Inpatient daily cost at haematology clinic. Code: VD010. 2015 [\n                    http:\/\/sodrasjukvardsregionen.se\/download\/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2015\n                    \n                  \/]."},{"issue":"2","key":"3683_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jac\/dkm196","volume":"60","author":"AJ Ament","year":"2007","unstructured":"Ament AJ, Hubben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, Van \u2018t Wout J, Severens JL. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother. 2007;60(2):385\u201393.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3683_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1600-0609.2008.01141.x","volume":"81","author":"WB Stam","year":"2008","unstructured":"Stam WB, O\u2019Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008;81(6):467\u201374.","journal-title":"Eur J Haematol"},{"issue":"14","key":"3683_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa040446","volume":"351","author":"TJ Walsh","year":"2004","unstructured":"Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391\u2013402.","journal-title":"N Engl J Med"},{"issue":"3","key":"3683_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ejh.12324","volume":"93","author":"A Leunis","year":"2014","unstructured":"Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93(3):198\u2013206.","journal-title":"Eur J Haematol"},{"key":"3683_CR34","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1038\/bcj.2016.3","volume":"6","author":"H Bower","year":"2016","unstructured":"Bower H, Andersson TM, Bjorkholm M, Dickman PW, Lambert PC, Derolf AR. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6:e390.","journal-title":"Blood Cancer J"},{"issue":"11","key":"3683_CR35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","volume":"33","author":"M Svensson","year":"2015","unstructured":"Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for Pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229\u201336.","journal-title":"Pharmacoeconomics"},{"key":"3683_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CEOR.S134230","volume":"9","author":"EM Adkins","year":"2017","unstructured":"Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;9:327\u201342.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"12","key":"3683_CR37","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","volume":"17","author":"A Skiada","year":"2011","unstructured":"Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859\u201367.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"3683_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","volume":"73","author":"N Azie","year":"2012","unstructured":"Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (prospective antifungal therapy) Alliance\u00ae registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293\u2013300.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"3683_CR39","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","volume":"50","author":"PG Pappas","year":"2010","unstructured":"Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101\u201311.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3683_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091\u2013100.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3683_CR41","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068\u201375.","journal-title":"Haematologica"},{"issue":"1","key":"3683_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s15010-013-0539-3","volume":"42","author":"MT Montagna","year":"2014","unstructured":"Montagna MT, Lovero G, Coretti C, Martinelli D, Delia M, De Giglio O, Caira M, Puntillo F, D\u2019Antonio D, Venditti M, et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection. 2014;42(1):141\u201351.","journal-title":"Infection"},{"key":"3683_CR43","first-page":"P1740","volume-title":"The cost of treating invasive mould disease caused by aspergillus and other filamentous fungi with isavuconazole compared with liposomal amphotericin B followed by posaconazole in the United Kingdom","author":"E Bagshaw","year":"2017","unstructured":"Bagshaw E, Enoch D, Micallef-Eynaud P, Blackney M, Posthumus P, Longshae C, Kuessner D. The cost of treating invasive mould disease caused by aspergillus and other filamentous fungi with isavuconazole compared with liposomal amphotericin B followed by posaconazole in the United Kingdom. Vienna: Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 2017. p. P1740."},{"key":"3683_CR44","first-page":"EP0396","volume-title":"The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis","author":"E Bagshaw","year":"2017","unstructured":"Bagshaw E, Blackney M, Heimann SM, Escrig C, Posthumus J, Kuessner D, Cornely OA. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis. Vienna: Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 2017. p. EP0396."},{"key":"3683_CR45","first-page":"A352","volume-title":"The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: economic evaluation of the phase III vital study and Fungiscope\u2122 matched case-control analysis","author":"E Bagshaw","year":"2017","unstructured":"Bagshaw E, Carotti A, Blackney M, Chiarini V, Posthumus J, Kuessner D. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: economic evaluation of the phase III vital study and Fungiscope\u2122 matched case-control analysis. Marseille: Presented at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation; 2017. p. A352."},{"issue":"1","key":"3683_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, Kowalski D, Lademacher C, Lewis W, Pearlman H, et al. Pharmacokinetic assessment of drug-drug interactions of Isavuconazole with the Immunosuppressants cyclosporine, mycophenolic acid, prednisolone, Sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76\u201385.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:07:48Z","timestamp":1581379668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3683-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DK and JP are employees of Basilea Pharmaceutica International Ltd., Switzerland and all hold stock options with Basilea.EB and LF report personal fees from Covance, who were commissioned by Basilea to carry out study analysis.JS has received personal fees from Unimedic for expert testimony, and from Pfizer and Gilead for lectures, all outside the scope of the current work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"134"}}